M&A / Deals Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors pharminent April 10, 2026
M&A / Deals Roche and C4 Therapeutics to advance degrader-antibody conjugates research pharminent April 10, 2026
M&A / Deals Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation pharminent April 10, 2026
M&A / Deals Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb pharminent April 9, 2026
M&A / Deals Roche sticks with C4T, adding up to $1B for molecular glue partnership pharminent April 9, 2026
M&A / Deals Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors pharminent April 9, 2026
M&A / Deals With 3 quick buyouts, Gilead leans into its latest transformation pharminent April 8, 2026
M&A / Deals Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities pharminent April 8, 2026
M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic pharminent April 8, 2026
M&A / Deals Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data pharminent April 8, 2026
M&A / Deals RoosterBio and MineBio team up to expand MSC solutions access in China pharminent April 8, 2026
M&A / Deals Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis pharminent April 7, 2026
M&A / Deals Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis pharminent April 7, 2026
M&A / Deals Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal pharminent April 6, 2026
M&A / Deals Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts pharminent April 3, 2026
M&A / Deals Biocytogen and Sihuan partner to advance new therapeutics for weight loss pharminent April 2, 2026
M&A / Deals Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets pharminent April 1, 2026
M&A / Deals Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes pharminent April 1, 2026
M&A / Deals Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B pharminent April 1, 2026
M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout pharminent March 31, 2026
M&A / Deals Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy pharminent March 31, 2026
